The ROR1 pseudokinase diversifies signaling outputs in MET-addicted cancer cells

International Journal of Cancer

Volumn 135, Issue 10, 2014, Pages 2305-2316

  Gentile, Alessandra ^a   Lazzari, Luca ^a   Benvenuti, Silvia ^a   Trusolino, Livio ^a,b   Comoglio, Paolo Maria ^a,b  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Oncogene addiction; Pseudokinase; Receptor tyrosine kinase; RTK; Transphosphorylation

Indexed keywords

CELL PROTEIN; PROLINE; PROTEIN ROR1; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; TYROSINE; UNCLASSIFIED DRUG; MET PROTEIN, HUMAN; PSEUDOKINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROR1 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; GENE SILENCING; MET GENE; ONCOGENE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SRC GENE; STRUCTURE ACTIVITY RELATION; ANIMAL; CELL CULTURE; CELL MOTION; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; GENETICS; HUMAN; IMMUNOPRECIPITATION; LENTIVIRINAE; METABOLISM; ONCOGENE ADDICTION; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PLASMID; PSEUDOGENE; RTK; STOMACH TUMOR; TRANSPHOSPHORYLATION; WESTERN BLOTTING;

ONCOGENE ADDICTION; PSEUDOKINASE; RECEPTOR TYROSINE KINASE; RTK; TRANSPHOSPHORYLATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; HUMANS; IMMUNOPRECIPITATION; LENTIVIRUS; PHOSPHORYLATION; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MET; PSEUDOGENES; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS;

EID: 84909945750     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28879     Document Type: Article

References (50)

1. Yarden Y, Shilo BZ. SnapShot: EGFR signaling pathway. Cell 2007;131:1018.
2. Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin is a transforming molecule that unleashes Met tyrosine kinase tumorigenesis. Cancer Res 2005;65:10674-9.
3. Trusolino L, Bertotti A, Comoglio PM. A signaling adapter function for alpha6beta4 integrin in the control of HGF-dependent invasive growth. Cell 2001;107:643-54.
4. Bertotti A, Comoglio PM, Trusolino L. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth. J Cell Biol 2006;175:993-1003.
5. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res 2011;71:3132-41.
6. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16.
7. Rebagay G, Yan S, Liu C, Cheung NK. ROR1 and ROR2 in human malignancies: potentials for targeted therapy. Front Oncol 2012;2:34.
8. Masiakowski P, Carroll RD. A novel family of cell surface receptors with tyrosine kinase-like domain. J Biol Chem 1992;267:26181-90.
9. Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell 2012;21:348-61.
10. Forrester WC. The Ror receptor tyrosine kinase family. Cell Mol Life Sci 2002;59:83-96.
11. Artim SC, Mendrola JM, Lemmon MA. Assessing the range of kinase autoinhibition mechanisms in the insulin receptor family. Biochem J 2012;448:213-20.
12. Murphy JM, Zhang Q, Young SN, et al. A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties. Biochem J 2014;457:323-34.
13. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell 2012;22:656-67.
14. Vigna E, Gramaglia D, Longati P, et al. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPRMET. Oncogene 1999;18:4275-81.
15. Michieli P, Basilico C, Pennacchietti S, et al. Mutant Met-mediated transformation is liganddependent and can be inhibited by HGF antagonists. Oncogene 1999;18:5221-31.
16. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell 1994;77:261-71.
17. Naldini L, Vigna E, Ferracini R, et al. The tyrosine kinase encoded by the MET proto-oncogene is activated by autophosphorylation. Mol Cell Biol 1991;11:1793-803.
18. Prat M, Crepaldi T, Gandino L, et al. C-terminal truncated forms of Met, the hepatocyte growth factor receptor. Mol Cell Biol 1991;11:5954-62.
19. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000;2:308-16.
20. Telford WG, Komoriya A, Packard BZ. Multiparametric analysis of apoptosis by flow and image cytometry. Methods Mol Biol 2004;263:141-60.
21. Breindel JL, Haskins JW, Cowell EP, et al. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res 2013;73:5053-65.
22. Follenzi A, Bakovic S, Gual P, et al. Cross-talk between the proto-oncogenes Met and Ron. Oncogene 2000;19:3041-9.
23. Li PP, Madhavan R, Peng HB. Differential regulation of axonal growth and neuromuscular junction assembly by HGF/c-Met signaling. Dev Dyn 2012;241:1562-74.
24. Navab R, Liu J, Seiden-Long I, et al. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells. Neoplasia 2009;11:1292-300.
25. Gonzatti-Haces M, Seth A, Park M, et al. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci USA 1988;85:21-5.
26. Ponzetto C, Zhen Z, Audero E, et al. Specific uncoupling of GRB2 from the Met receptor. Differential effects on transformation and motility. J Biol Chem 1996;271:14119-23.
27. Blom N, Gammeltoft S, Brunak S. Sequence and structure-based prediction of eukaryotic protein phosphorylation sites. J Mol Biol 1999;294:1351-62.
28. Takahashi T, Fournier A, Nakamura F, et al. Plexin-neuropilin-1 complexes form functional semaphorin-3A receptors. Cell 1999;99:59-69.
29. Bertotti A, Bracco C, Girolami F, et al. Inhibition of Src impairs the growth of met-addicted gastric tumors. Clin Cancer Res 2010;16:3933-43.
30. Gentile A, Trusolino L, Comoglio PM. The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev 2008;27:85-94.
31. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.
32. Hayakawa F, Naoe T. SFK-STAT pathway: an alternative and important way to malignancies. Ann N Y Acad Sci 2006;1086:213-22.
33. Boccaccio C, Andò M, Tamagnone L, et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature 1998;391:285-8.
34. Bivona TG, Pérez De Castro I, Ahearn IM, et al. Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1. Nature 2003;424:694-8.
35. Zhang H, Photiou A, Grothey A, et al. The role of pseudokinases in cancer. Cell Signal 2012;24:1173-84.
36. Huang PH, Mukasa A, Bonavia R, et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 2007;104:12867-72.
37. Bertotti A, Comoglio PM. Tyrosine kinase signal specificity: lessons from the HGF receptor. Trends Biochem Sci 2003;28:527-33.
38. Akbarzadeh S, Wheldon LM, Sweet SM, et al. The deleted in brachydactyly B domain of ROR2 is required for receptor activation by recruitment of Src. PLoS One 2008;3:e1873.
39. Mueller KL, Hunter LA, Ethier SP, et al. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells. Cancer Res 2008;68:3314-22.
40. Guo W, Pylayeva Y, Pepe A, et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell 2006;126:489-502.
41. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010;11:834-48.
42. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008;123:1190-5.
43. Fukuda T, Chen L, Endo T, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc Natl Acad Sci USA 2008;105:3047-52.
44. Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res 2008;14:396-404.
45. Shabani M, Asgarian-Omran H, Omran HA, et al. Overexpression of orphan receptor tyrosine kinase Ror1 as a putative tumor-associated antigen in Iranian patients with acute lymphoblastic leukemia. Tumour Biol 2007;28:318-26.
46. Choudhury A, Derkow K, Daneshmanesh AH, et al. Silencing of ROR1 and FMOD with siRNA results in apoptosis of CLL cells. Br J Haematol 2010;151:327-35.
47. Tyner JW, Deininger MW, Loriaux MM, et al. RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci USA 2009;106:8695-700.
48. Cui B, Zhang S, Chen L, et al. Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis. Cancer Res 2013;73:3649-60.
49. Carragher NO, Frame MC. Focal adhesion and actin dynamics: a place where kinases and proteases meet to promote invasion. Trends Cell Biol 2004;14:241-9.
50. Bertotti A, Burbridge MF, Gastaldi S, et al. Only a subset of Met-activated pathways are required to sustain oncogene addiction. Sci Signal 2009;2:er11.